September 3, 2008 -
Biologic Lung Volume Reduction (BLVR) System Trial Achieves Primary Efficacy Endpoint; Preparations for Phase 3 Trials are Underway –
Aeris Therapeutics, Inc., a company specializing in the development and commercialization of novel treatments for patients with emphysema and other advanced lung diseases, announced that the primary efficacy endpoint in Phase 2 clinical trials for its Biologic Lung Volume Reduction (BLVR) System has been achieved. BLVR is designed to provide a safe non-surgical alternative to lung volume reduction surgery, one of the few available treatments for patients with advanced emphysema. The BLVR system is the first biologic therapy that has been successfully used to remodel the lung and improve breathing function...
Aeris Therapeutics' Press Release -
September 23, 2008 - Kuros Biosurgery AG and Aeris Therapeutics, Inc., both privately held biotech companies, announced today that Kuros has granted Aeris an exclusive license in the field of lung volume reduction to certain patent rights Kuros exclusively licensed from the American Red Cross that cover the delivery of certain drugs in a fibrin sealant. In return for the license, Kuros will receive upfronts, milestones and royalties on the sale of Aeris’ lead product, the AeriSeal™ Biologic Lung Volume Reduction (BLVR) System, a novel investigational emphysema treatment. Aeris is currently preparing for the initiation of Phase 3 clinical trials for the AeriSeal BLVR system...
[PDF] Kuros Biosurgery's Press Release - Aeris Therapeutics' Press Release -
